CONDENSED CONSOLIDATED STATEMENTS OF OPERATIONS (USD $) In Thousands, except Share data, unless otherwise specified	3 Months Ended		88 Months Ended
	Mar. 31, 2013	Mar. 31, 2012	Mar. 31, 2013
Costs and Expenses:
Research and development	$ 14,344	$ 5,338	$ 72,051
Purchased in-process research and development			29,157
General and administrative	3,278	1,732	30,863
Loss from Operations	(17,622)	(7,070)	(132,071)
Interest and investment income	18	39	514
Interest expense			(12)
Other income			1,363
Change in fair value of derivative instruments-warrants	(1,093)	8	2,528
Total Other (Loss)/Income	(1,075)	47	4,393
Loss from Continuing Operations	(18,697)	(7,023)	(127,678)
Loss from Discontinued Operations			(72)
Net Loss	$ (18,697)	$ (7,023)	$ (127,750)
Weighted Average Common Shares Outstanding Basic and Diluted (in shares)	72,789,006	54,298,079
Net Loss per Common Share, Basic and Diluted
Net Loss per Common Share, Basic and Diluted (in dollars per share)	$ (0.26)	$ (0.13)